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I. INTRODUCTION 
The Republic of Korea (Korea)1 modified the Korean Patent 
Act in 1986 to allow pharmaceutical products as patentable subject 
matter. Since then, the size of the Korean pharmaceutical market,2 
its potential growth rate,3 and the increasing amount of interstate 
trade between Korea and United States4 has made it attractive for 
U.S. pharmaceutical companies. U.S. pharmaceutical companies 
could realize substantial profits from the international trade.5 
However, approaching the Korean pharmaceutical market has 
become more demanding than before because profit may increase 
or decrease depending on what strategies a company takes. Among 
such strategies is obtaining patent protection over high-value 
pharmaceuticals to prevent competition from generic drugs. 
                                                 
1
 The Republic of Korea, commonly known as South Korea, will be 
referred to as Korea. The contents of this paper have no relevance to North 
Korea, which is officially known as the Democratic People’s Republic of Korea. 
2
 See UNITED STATES INTERNATIONAL TRADE COMMISSION, PUB. NO. 
3949,U.S.–KOREA FREE TRADE AGREEMENT: POTENTIAL ECONOMY-WIDE AND 
SELECTED SECTORAL EFFECTS, INV. NO. TA-2104-24, 64 (Sept. 2007) 
(Corrected) [hereinafter USITC] (“Korea's pharmaceutical market is ranked 
among the world's top 12 pharmaceutical markets and is worth approximately $8 
billion annually.”).  
3
 See id. (“Sustained growth in the market is expected as the Korean 
population ages.”). 
4
 See Yong-Shik Lee et al., The United States - Korea Free Trade 
Agreement: Path to Common Economic Prosperity or False Promise?, 6 E. 
ASIA L. REV. 111, 113 (2011) (“The historic U.S.-Korea Free Trade Agreement 
(FTA), which is the largest FTA since the North American Free Trade 
Agreement (NAFTA) and the first FTA between major trading nations in North 
America and Asia, was agreed upon on April 2, 2007 after 14 months of 
negotiations, and signed on June 30, 2007.”). 
5
 See USITC, supra note 2 (“U.S. exports of pharmaceutical products to 
Korea were valued at $351 million in 2006. In that year, the United States 
accounted for 15.8% of Korea's imports of pharmaceutical products.”). 
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This article is intended to help U.S. practitioners in building 
their own legal strategies. Part I of this article will discuss the 
invalidation of Korean pharmaceutical patents based on decisions 
from the Korean Supreme Court. Knowing such trends will 
provide practitioners (1) an opportunity to approach Korean 
pharmaceutical industry more efficiently and (2) an idea of what to 
expect in near future. 
Part II of this article will discuss the general definition and 
legal standard of “selection invention,” which is a class of 
inventions where a known molecule may, in certain circumstances, 
satisfy the inventive step requirement under Korean patent law.6 
Part III of this article will introduce the Korean Supreme Court’s 
decisions as to selection invention, which have been consistently 
strict against patent holders.7 Finally, Part IV of this article will 
provide a legal explanation and policy justifications for such a 
strict patentability standard with respect to selection invention.8 
II. SELECTION INVENTION 
A primary purpose and effect of “selection invention” or 
“selective invention” is to grant a patent right over species when 
all or part of its genus are known to the public or disclosed in the 
prior art.9 The official Korean jurisdiction uses nomenclatures of 
                                                 
6
 See infra Part II; see also Patrick P. Hansen & Donald J. Featherstone, A 
Brief Review of U.S. and Korean Patent Invalidity Decisions for CMP Slurry 
Patents, 8 NANOTECHNOLOGY L. & BUS. 85, 89 (2011) (“In Korea, selection 
inventions are becoming very important in the pharmaceutical field, as many 
new drugs are based on improvements to known molecules and compounds.”) 
7
 See infra Part III. 
8
 See infra Part IV. 
9
 See Jay A. Erstling & Ryan E. Strom, Korea's Patent Policy and Its 
Impact on Economic Development: A Model for Emerging Countries?, 11 SAN 
DIEGO INT'L L.J. 441, 452 (2010); see also Supreme Court [S. Ct.], 
2001Hu2740, Apr. 25, 2003 (S. Kor.) (“The so-called selective invention means 
an invention which states the element of the preceding or already publicized 
invention as its superordinate concept and whose elements entirely or partly 
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“superordinate concept” and “subordinate concept,” 10  which 
corresponds respectively to “genus” and “species.” Hereinafter, 
due to reader’s familiarity, the article will consistently use 
nomenclatures of genus and species. 
A. Novelty 
The Korean Patent Act does not explicitly define “novelty”11; 
however, article 29 defines “prior art” and states that an invention 
may be patentable unless it is anticipated by the prior art. 12 
Generally, in selection invention, novelty is destroyed when a prior 
art reference discloses a chemical composition that is the subject 
matter of an invention. The Korean Supreme Court has held that a 
prior art reference also discloses the composition when the 
composition is such that it would have been “recognizable” at the 
time of the filing date to a person having ordinary skill in the art.13 
Therefore, the destruction of novelty may also occur when the 
prior art discloses a structurally similar chemical compound to the 
subject matter of a claimed invention. 
                                                                                                             
consist of subordinate concepts derived from the above superordinate 
concept.”). 
10
 Translated authority provided by Korean Intellectual Property Office uses 
subordinate concept and superordinate concept in defining selection invention. 
The subordinate–superordinate relationship corresponds to the genus-species 
relationship. See Supreme Court [S. Ct.], 2001Hu2740, Apr. 25, 2003 (S. Kor.).  
11
 Erstling, supra note 9, at 450. 
12
 Id. at 471 n.163; see also Teukheo beob [Patent Act], Act. No. 950, Dec. 
31, 1961, art. 29.1-.2 (S. Kor.) (“Inventions having industrial applicability may 
be patentable unless they fall under any of the following subparagraphs: 1. 
Inventions publicly known or worked in the Republic of Korea or in a foreign 
country prior to the filing of the patent application; 2. Inventions described in a 
publication distributed in the Republic of Korea or in a foreign country prior to 
the filing of the patent application or inventions made accessible to the public 
through telecommunication lines prescribed by Presidential Decree.”). 
13
 Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 15, 2009 (S. 
Kor.). 
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Korean courts have been consistently hostile toward patentees 
in applying this novelty standard.14 This is especially true when the 
claimed composition is structurally similar to the prior art. 15 
Currently, a prior art reference disclosing a certain molecule16 will 
likely destroy the novelty of a mirror-image molecule17 or its salt,18 
regardless of substantive differences in chemical properties 
between the two molecules.19 
B. Inventiveness 
“Inventive step” or “inventiveness” is analogous to the concept 
of non-obviousness in U.S. patent law.20 Article 29.2 of the Korean 
Patent Act provides that an invention is not patentable when a 
person having ordinary skill in the art could easily have made the 
                                                 
14
 See Hansen & Featherstone, supra note 6, at 89 (“Similarly, Korean 
patentees have faced hurdles such as high standards for patentability. For 
example, the Korean Supreme Court decision in Sanofi-Aventis v. CJ set forth 
extremely strict standards for the patentability of selection inventions.”). 
15
 The Korean courts have generally rejected patentability or invalidated the 
patent of a chemical composition that is structurally similar to that of the prior 
art. See, e.g., Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 15, 2009 
(S. Kor.); Supreme Court [S. Ct.], 2008Hu3520, Mar. 25, 2010 (S. Kor.). 
16
 See infra Part. III.A.1.i. 
17
 See Supreme Court [S. Ct.], 2008Hu3520, Mar. 25, 2010 (S. Kor.) 
(holding that disclosing a chemical equation of heptanoic acid enantiomer in its 
embodiment destroys patentability of an invention of which heptanoic acid 
enantiomer is a subject since a person having ordinary skill in the art will easily 
recognize the existence of heptanoic acid enantiomer). 
18
 See Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 15, 2009 
(S. Kor.) (denying a patentability of an enantiomer as the hydrochloride salt 
when the prior art discloses racemate as the hydrochloride salt). 
19
 Merely disclosing the chemical equation of a composition in the 
specification may destroy the novelty of an invention of which the composition 
is a subject matter. See id. (“It is not necessary that the comparison invention 
No. 1 disclose the method of separation or the possibility of separation as 
alleged in the plaintiff’s ground of appeal.”). 
20
 Erstling, supra note 9, at 451.  
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invention prior to the filing of the patent application.21 In selection 
invention, an invention will be considered to possess inventiveness 
if there is either “qualitative” or “conspicuously quantitative 
difference” in effect between the prior art and the invention.22 
Some commentators refer to a “conspicuous quantitative 
difference” as “superior working effect over the prior art.”23 
“Qualitative difference” refers to differences between the 
medicinal purpose of the invention and that of the prior art. 24 
Therefore, there is no “qualitative difference” if there are 
significant similarities between a medicinal purpose of the claimed 
composition and that of the prior art. 25  However, a claimed 
composition, which is qualitatively similar to a prior art, still 
possesses inventiveness if its working effect is superior over that of 
the prior art.26 The Korean Supreme Court has set a very high 
                                                 
21
 Teukheo beob [Patent Act], Act. No. 950, Dec. 31, 1961, art. 29.2 (S. 
Kor.). 
22
 See Supreme Court [S. Ct.], 2001Hu2740, Apr. 25, 2003 (S. Kor.) 
(“[S]ubordinate concepts possess either effects different in quality from the 
preceding invention, or there exist conspicuous differences in effect as measured 
quantitatively between them.”). 
23
 The biggest law firm in Korea, Kim and Chang, uses “superior working 
effect” to describe invention’s qualitative difference over the prior art. See 
generally Jay Young-June Yang, Jay J. Kim & Mee Sung Shim, The Korean 
Supreme Court Applies Strict Patentability Standards Against Selection 
Inventions, KIM & CHANG QUARTERLY UPDATE OF KOREAN IP LAW & POLICY, 
Mar. 25, 2010, at 1-3, available at http://www.ip.kimchang.com/ip/
frame2.jsp?lang=2&b_id=113&m_id=161. 
24
 See Supreme Court [S. Ct.], 2001Hu2740, Apr. 25, 2003 (S. Kor.); see 
also Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 15, 2009 (S. 
Kor.) (discussing "differences in quality"). 
25
 See Supreme Court [S. Ct.], 2002Hu2846, Dec. 10, 2003 (S. Kor.) 
(denying patentability of a selection invention because it shared a common 
medicinal purpose with the prior art). 
26
 Supreme Court [S. Ct.], 2001Hu2740, Apr. 25, 2003 (S. Kor.) (“A patent 
can be granted to a selective invention on the conditions that . . . subordinate 
concepts possess effects different in quality from the preceding invention, or if 
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standard for working effect when a claimed composition is 
structurally similar to those shown in the prior art. Therefore, it is 
extremely hard for an applicant or patentee to claim patentability 
of an invention if the claimed composition is, for example, a 
certain isomer (mirror image) or salt of a known chemical 
compound.27 
C. Disclosure Requirement 
For the selection invention category, an invention is not 
patentable unless the patent application explicitly discloses either 
qualitative or quantitative working effects in its specification.28 
Explicitly stating such effects means either (1) the specification 
must be specific as to the qualitative differences that any such 
difference be verifiable, or (2) that the specification quantitatively 
describes the invention’s working effect as to verify that such 
effect is superior. 29  Merely stating that an invention is “very 
excellent” compared to the preceding invention will not suffice.30 
Further, such information must be more than stating the claimed 
composition’s typical physical properties that are naturally 
considered by a person having ordinary skill in the art. 31 
                                                                                                             
not, at least, there exist conspicuous differences in effect as measured 
quantitatively between them.”). 
27
 See, e.g., Supreme Court [S. Ct.], 2001Hu2740, Apr. 25, 2003 (S. Kor.); 
Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 15, 2009 (S. Kor.); 
Supreme Court [S. Ct.], 2008Hu3520, Mar. 25, 2010 (S. Kor.). 
28
 Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 15, 2009 (S. 
Kor.) (“[T]he detailed description of the selective invention must explicitly state 





 Supreme Court [S. Ct.], 2005Hu3338, Sept. 6, 2007 (S. Kor.). 
31
 See Supreme Court [S. Ct.], 2008Hu3469 & 3476 (consol.), Mar. 25, 
2010 (S. Kor.) (holding that the application has failed to meet disclosure 
requirement when it disclosed nothing “other than physical nature that an 
ordinary technician naturally considers when he or she makes salt compounds of 
medicinal substance.”). 
8
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Subsequent cases seem to require that such difference be verifiable 
to a person having ordinary skill in the art. 32  The applicant or 
patentee needs not undergo any experiments verifying such 
superior working effect; instead, explicitly disclosing such working 
effect will suffice unless suspicions as to its superior working 
effects are raised. 33  If there are suspicions as to the claimed 
composition’s effects, the applicant or patentee can overcome them 
by submitting specific comparative experimental data. 34  Such 
comparative experimental data must relate to the claimed 
composition’s intended medicinal purpose.35 
III. PATENTABILITY STANDARD OF PHARMACEUTICAL PRODUCTS 
While there are few Korean Supreme Court decisions regarding 
selection invention,36 the Korean Supreme Court has addressed the 
                                                 
32
 See generally Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 
15, 2009 (S. Kor.). 
33
 See Supreme Court [S. Ct.], 2001Hu2740, Apr. 25, 2003 (S. Kor.) (“[I]t 
is enough that the specifications of a selective invention state explicitly the 
above mentioned kinds of effects compared to the preceding invention, and the 
results of comparative experiments verifying conspicuousness of its effects in 
concrete need not be stated.”). 
34
 See id. (“[I]f suspicions as to its effects are raised, an applicant for a 
patent may allege and prove its effects after the date of patent application by 
means of submitting specific comparative experimental data, etc.”). 
35
 See Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 15, 2009 
(S. Kor.) (stating that acute toxicity experiment is not relevant in proving 
invention’s superior working effect since “it is just significant in examining 
whether it can be used as a medicinal product.”). 
36
 Such cases include: Supreme Court [S. Ct.], 2001Hu2375, Dec. 26, 2002 
(S. Kor.); Supreme Court [S. Ct.], 2001Hu2740, Apr. 25, 2003 (S. Kor.); 
Supreme Court [S. Ct.], 2002Hu1935, Oct. 24, 2003 (S. Kor.); Supreme Court 
[S. Ct.], 2002Hu2846, Dec. 10, 2003 (S. Kor.); Supreme Court [S. Ct.], 
2005Hu3338, Sept. 6, 2007 (S. Kor.); Supreme Court [S. Ct.], 2008Hu3469 & 
3476, Mar. 25, 2010 (S. Kor.); Supreme Court [S. Ct.], 2008Hu736 & 743 
(consol.), Oct. 15, 2009 (S. Kor.); Supreme Court [S. Ct.], 2008Hu3520, Mar. 
25, 2010 (S. Kor.); Supreme Court [S. Ct.], 2010Hu3424, Nov. 5, 2010 (S. 
Kor.). 
9
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issue at various times since 200237  and, most recently, in 201038. 
A recurring discussion in the Korean Supreme Court’s holdings is 
whether selection inventions are, in fact, patentable.  
Several important trends have emerge from these decisions and 
are worthy of note. First, the Korean Supreme Court has 
historically invalidated patents on selection inventions and, until 
recently, a patentee had never prevailed at the highest court.39 
Second, while the earliest case on this issue was a dispute between 
individuals, the rest of the cases were disputes between non-
Korean pharmaceutical companies and either the Korean 
Intellectual Property Office (KIPO) or Korean pharmaceutical 
companies.40 Third, the patentee or patent applicant against whom 
the Korean Supreme Court has held was always a non-Korean 
pharmaceutical company. In summary, a non-Korean 
pharmaceutical company had never successfully defended a 
selection invention at the Korean Supreme Court until one very 
recent opinion.41 This section will discuss Sanofi-Aventis v. CJ et 
al. (Sanofi)42 as it is the strictest and arguably most unreasonable 
in terms of its patentability standard. This section will further 
discuss the impact of Sanofi by analyzing Korean Supreme Court’s 
decisions regarding selection invention thereafter. 
                                                 
37
 Supreme Court [S. Ct.], 2001Hu2375, Dec. 26, 2002 (S. Kor.). 
38
 Supreme Court [S. Ct.], 2010Hu3424, Nov. 5, 2010 (S. Kor.). 
39
 See id. (reversing and remanding the Korean Intellectual Property 
Tribunal and Patent Court’s holding, which denied the invention’s 
inventiveness). 
40
 See Supreme Court [S. Ct.], 2001Hu2375, Dec. 26, 2002 (S. Kor.). 
41
 For the First time, the Korean Supreme Court in 2010Hu3424 held in 
favor of the non-Korean Company. See Supreme Court [S. Ct.], 2010Hu3424, 
Nov. 5, 2010 (S. Kor.).  
42
 Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 15, 2009 (S. 
Kor.). 
10
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A. Sanofi Patent 
The Korean Supreme Court’s consistent, strict application of 
the novelty and inventiveness standards reflects the its hostility 
against patentees and patent applicants. Such tendency peaked in 
the Sanofi case, 43  in which the Korean Supreme Court set 
extremely high novelty and inventiveness standards.44 This section 
will provide a scientific background to the invention in Sanofi, 
followed by a case summary and discussion of its significance. 
1. Scientific Background 
The issue in Sanofi was the patentability of an enantiomer 
patent in light of the applicant’s prior patent directed towards a 
racemate. This section will provide general understanding of 
nomenclatures such as enantiomer and racemate, which are key 
concepts to understand dispute in Sanofi. 
i. Enantiomers and Racemates 
The term chirality refers to a geometric property of an object 
that is not identical to its mirror image, for example, a person’s 
right and left hands. 45  When molecules are chiral, the same 
chemical formula can describe molecules with different three-
dimensional structures. 46  Enantiomers are chiral molecules of 
opposite orientation with only one point of chirality.47 
Again, the concept of enantiomers, non-identical mirror 
images, is illustrated by a person’s right and left hands. The right 
and left hands are mirror images of each other, but they are not 
                                                 
43
 Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 15, 2009 (S. 
Kor.). 
44
 See Yang et al., supra note 23, at 1. 
45
 Jonathan McConathy & Michael J. Owens, Stereochemistry in Drug 
Action, 5 PRIMARY CARE COMPANION J. CLIN. PSYCHIATRY 70, 70 (2003). 
46
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superimposable and thus not identical. Similarly, enantiomers are 
identical in their chemical composition and structure in two 
dimensional spaces, but are not superimposable as they are not 
identical in their orientation in three dimensional spaces.48  
A racemate is a mixture of those enantiomers, usually in equal 
amounts.49 When an active ingredient of a drug is in the form of an 
enantiomer, the drug is usually referred to as an enantiomer drug. 
Vice versa, a racemate drug refers to a drug of which the active 
ingredient is in the form of a racemate. Further, patents covering 
enantiomer drugs are referred to as enantiomer patents, whereas a 
racemate patent refers to a patent primarily covering a racemate 
drug. 
Although there is a high degree of structural similarity between 
racemates and enantiomers, racemates and enantiomers may differ 
greatly in a terms of biological and pharmaceutical properties.50 
Two enantiomers constituting a racemate may also differ 
significantly in various respects51 because the active site of certain 
enzymes may only react to one enantiomer and not the other,52 
similar to how a right-handed glove does not fit on a person’s left 
hand. Therefore, academic tendency is to view two enantiomers as 
two separate properties unless proven otherwise. 53  Further, an 






 See id. at 71 (“In these cases, it is critical to distinguish the single 
enantiomer from the racemic form because they may differ in their dosages, 
efficacies, side effect profiles, or even indicated use.”). 
51
 Id. at 72 (“The 2 enantiomers of a chiral drug may differ significantly in 
their bioavailability, rate of metabolism, metabolites, excretion, potency and 
selectivity for receptors, transporters and/or enzymes, and toxicity.”). 
52
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enantiomer’s pharmaceutical activity can be unpredictable absent 
clinical trials and experiences.54 
a. Pharmaceutical Practice 
In the preparation of pharmaceuticals, laboratory synthesis of 
chiral molecules initially results in racemate drugs. 55  Thus, 
pharmaceutical companies must separate the enantiomers from one 
another before investigating the pharmaceutical activities of the 
enantiomer drugs. The problem is that separating the enantiomers 
is usually difficult,56 and pharmaceutical companies often spend 
significant time and money on separation.57 Therefore, evidence 
that a company has successfully separated the enantiomers from 
the racemate may facilitate patentability if the jurisdiction places 
weight on the separation effort and process. 
2. Procedural Background 
i. History of Plavix® 
In 1972, while seeking an agent that might have improved anti-
inflammatory properties, Sanofi-Aventis (Aventis) scientists 
discovered that compounds known as thienopyridines have the 
property of inhibiting blood platelet aggregation. 58  Thereafter, 
                                                 
54
 See id. at 72 (“The decision to use a single enantiomer versus a mixture 
of enantiomers of a particular drug should be made on the basis of the data from 
clinical trials and clinical experience.”). 
55
  Jonathan J. Darrow, The Patentability of Enantiomers: Implications for 
the Pharmaceutical Industry, 2007 STAN. TECH. L. REV. 2, 9 (2007). 
56
 See id. (“Due to the difficulty in separating the enantiomers from one 
another, many chiral drugs were initially sold in racemic form.”). 
57
 For instance, Sanofi had given up commercial development of the 
racemate PCR 4099, which “had been proceeding since 1980 and had reached 
Phase I human trials at a cost stated to be tens of millions of dollars,” to develop 
enantiomer of PCR 4099, which also took years. Sanofi-Synthelabo v. Apotex, 
Inc., 550 F.3d 1075, 1081 (Fed. Cir. 2008). Therefore, a racemate patent usually 
precedes an enantiomer patent. 
58
 Id. at 1078. 
13
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Aventis scientists continuously put effort into finding chemical 
modifications and derivatives of thienopyridines in order to 
discover optimum anti-platelet aggregation properties with 
minimal undesirable effects.59 
Sanofi eventually selected a compound designated as PCR 
4099 for commercial development.60 Further, Aventis found that a 
hydrochloride salt of the compound was suitable for tableting PCR 
4099.61 Aventis filed a patent application covering PCR 4099 as a 
hydrochloride salt in a number of countries including the United 
States and Korea.62  However, as PCR 4099 still raised toxicity 
issues, Aventis continued its research toward finding a more 
optimum version of the agent.63 
Aventis’s subsequent research focused on separating PCR 
4099, which was a racemate mixture, into enantiomers, and 
Aventis discovered that, after spending significant time and money 
on separation, one of the enantiomers provided all of the favorable 
antiplatelet activity without significant neurotoxicity. 64  Aventis 
named that enantiomer “Clopidogrel.”65  Aventis also found that 
hydrochloride salt, which had been suitable for tableting the PCR 
4099, was not suitable for Clopidogrel.66 Aventis’s research also 
revealed that bisulfate was suitable for tableting Clopidogrel.67 
                                                 
59
 Id. at 1078-79. 
60
 Id. at 1079. 
61
 Id. at 1082. 
62
 Id.; Patent Court [Pat. Ct.], 2006Heo6303 & 8330, Jan. 18, 2008 (S. 
Kor.). 
63
 Sanofi-Synthelabo v. Apotex, Inc., 550 F.3d 1075, 1079 (Fed. Cir. 2008).  
64
 Id. at 1081. 
65
 Id. at 1081-82 (“More years of development ensued for the 
dextrorotatory enantiomer, to which Sanofi gave the common name 
Clopidogrel.”). 
66
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Thereafter, Aventis filed a patent application covering Clopidogrel 
as the bisulfate (Clopidogrel Bisulfate) in the United States and 
Korea, as well as other countries. 68  Later, Aventis launched 
Plavix®, which included Clopidogrel bisulfate as an active 
ingredient.69 
ii. Judicial History 
KIPO granted Aventis a patent (the ’448 patent)70  covering 
PCR 4099 in 1983. Five years later, Aventis filed another patent 
application71 covering Clopidogrel and its salt, and was granted a 
patent (the ’969 patent).72 To summarize, the earlier ’448 patent is 
a racemate patent while the subsequent ’969 patent is an 
enantiomer patent. 
As a result of the successful filing of the ’969 patent, other 
pharmaceutical companies were prohibited from producing generic 
products of Plavix® so long as either the ’448 or ’969 patent 
survived.73 After 2003, the ’969 patent prevented other 




 Id. at 1077. 
70
 Kor. Patent No. 1,019,840,005,448 (filed Jul. 13, 1982); FAQ - Korea, 
EUROPEAN PATENT OFFICE, http://www.epo.org/searching/asian/korea/
faq.html#faq-406 (last updated Mar. 10, 2011) (Korean patents have a term of 
protection of 20 years from the date of the filing).  
71
 Kor. Patent No. 1,019,880,009,969 (filed Feb. 17, 1987). 
72
 The ‘969 patent claimed Clopidogrel in its claim 1, and further claimed 
Clopidogrel as the hydrochloride salt and hydrogen sulfite salt respectively in 
claim 2 and 3. Therefore, the nature of the subject matter broadly presents two 
issues before the Korean Supreme Court: first, whether an enantiomer of 
chemical compound is patentable when the prior art discloses its racemate; and 
second, whether the enantiomer as the specific salt is patentable when the prior 
art disclose the racemate as the salt. Supreme Court [S. Ct.], 2008Hu736 & 743 
(consol.), Oct. 15, 2009 (S. Kor.). 
73
 See DONG-YUN KIM, KOREAN ECONOMICS, A DISPUTE BETWEEN 
KOREAN AND FOREIGN PHARMACEUTICAL COMPANIES, http://
sgsg.hankyung.com/apps.frm/news.view?nkey=2562&c1=03&c2=06. 
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pharmaceutical companies from producing generic versions of 
Plavix®.74 While generic versions of Plavix® would have been 
prohibited until 2011, seventeen Korean pharmaceutical companies 
sought to remove this barrier early by invalidating the ’969 
patent. 75  The main argument was that the ’969 patent was 
anticipated by the ’448 patent.76 The Korean Intellectual Property 
Tribunal and Patent Court held the ’969 patent invalid, and Aventis 
appealed the case to the Korean Supreme Court.77 
iii. Holding 
In Sanof, the Korean Supreme Court affirmed the Korean 
Intellectual Property Tribunal and Patent Court’s holding, which 
invalidated the ’969 patent by denying its novelty and 
inventiveness.78 With respect to claim 1 of the ’969 patent, the 
Korean Supreme Court denied Clopidogrel’s novelty as anticipated 
by the ’448 patent because the ’448 patent covered the 
Clopidogrel.79 With respect to claim 2, the Korean Supreme Court 
held that, because the ’448 patent discloses the Clopidogrel and 
PCR 4099 as the hydrochloride salt, the Clopidogrel as the 
hydrochloride salt is easily recognizable to a person having 
ordinary skill in the art in a light of the ’448 patent.80 
As to claim 3, the Korean Supreme Court compared the subject 
matter’s pharmaceutical working effect with that of PCR4099 as 
the hydrochloride salt, which was disclosed in the ’448 patent. The 
Korean Supreme Court held that a two-fold pharmaceutical 
                                                 
74
 See infra Part. V.B.1.ii. 
75
 Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 15, 2009 (S. 
Kor.). 
76
 See Yang et al., supra note 23, at 2. 
77
 See Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 15, 2009 
(S. Kor.). 
78
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working effect of the invention compared to that of the prior art 
was not superior since it was widely known that a certain 
enantiomer may have greater working effect than that of a 
racemate or another corresponding enantiomer.81 
3. Significance 
Sanofi is significant in two respects. First, it was the first 
Korean Supreme Court case to determine the patentability of an 
enantiomer patent. Second, it set an extremely high standard of 
patentability for selection inventions. Opinions vary regarding 
what makes Sanofi strict as to patentability. Some argue that it 
heightened the novelty requirement. 82  Others argue, mistakenly, 
that it denied the invention’s patentability for lack of written 
description about quantitative differences, despite an actual 
superior working effect.83 One may also argue that the decision is 
strict because its literal impact is to deny patentability of a certain 
composition merely because a degree of its working effect is well-
known.84 
i. Heightened Novelty Standard 
One may argue that the novelty standard set by Sanofi is much 
stricter than that used in other leading patent jurisdictions.85 Such 
an argument is well-supported by the fact that the current Korean 
common law will likely invalidate an enantiomer patent if a prior 
racemate patent mentions the existence of the subsequently 








 See generally Cha-Ho Jung & Hyeen Shin, Legal Review on Selection 
Invention’s Novelty of Optical Isomer, 49 SEOUL NAT’L U. L. REV. 355 (2000). 
85
 See Yang et al., supra note 23, at 2 (“First, its novelty standard is much 
stricter than those in other leading patent jurisdictions. Here, the Court held that 
an enantiomer per se and its medicinal use lacks novelty over a prior art 
racemate and its medicinal use – by comparison, the novelty of the enantiomer’s 
medicinal use would be upheld in Japan.”). 
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claimed enantiomers that comprise the racemate. 86  In contrast, 
some countries have undergone deeper analysis, and sometimes 
have upheld the novelty of an enantiomer patent regardless of the 
raceamte patent’s mentioning of the enantiomers. For example, 
some courts look at whether (1) the species of certain genus are so 
characteristically (not structurally) similar that disclosure of a 
genus in the prior art is necessarily a disclosure of every species,87 
or (2) the method of separating a certain optical isomer from its 
racemate is well-known or specifically disclosed.88 Korea instead 
applied a per se analysis resulting in an extremely heightened 
standard for selection invention novelty for enantiomer patents. 
ii. Heightened Inventiveness Standard 
One may also argue that Sanofi created a significantly 
heightened inventiveness standard. Such an argument is supported 
by the fact that the Korean Supreme Court held that a two-fold 
superior working effect is not sufficient when such superior 
working effect is obvious. 89  Therefore, one impact of Sanofi’s 
holding is to require, at a minimum, a two-fold working effect for 
the enantiomer drug to be “superior.” 
iii. Lack of Description of Qualitative Difference 
Some argue that the Sanofi decision is strict because the 
Korean Supreme Court denied inventiveness of the patent for lack 
of description as to quantitative differences in the specification 
despite the invention’s actual superior working effects over the 
                                                 
86
 See Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 15, 2009 
(S. Kor.); see also infra Part. V.A.2.ii. 
87
 See Atofina v. Great Lakes Chem. Corp., 441 F.3d 991, 999 (Fed. Cir. 
2006) (“It is well established that the disclosure of a genus in the prior art is not 
necessarily a disclosure of every species that is a member of that genus.”). 
88
 See EPO Case T-0296/87 (Aug. 30, 1988), available at http://
www.epo.org/law-practice/case-law-appeals/recent/t870296ep1.html. 
89
 See Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 15, 2009 
(S. Kor.); see also infra Part. IV.A.2.a. 
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prior art.90 However, such an argument is flawed since a lack of 
description as to quantitative difference was not an issue in the 
case. Rather, the Korean Supreme Court stated that the invention’s 
qualitative difference over the prior art was clearly described in the 
specification.91 Therefore, such arguments may have been made 
due to confusion between quantitative and qualitative differences. 
IV. POST-SANOFI DECISIONS 
Sanofi was very influential in terms of legal impact. All three 
subsequent Korean Supreme Court cases involving selection 
invention cite Sanofi as binding precedent in reviewing the novelty 
of an invention at issue.92 Two of those cases denied the novelty 
pursuant to Sanofi.93 This section will discuss these two cases.94 
A. Warner-Lambert Co. Patent 
In 2008, the Korean Supreme Court dealt with another 
selection invention patent case in which enantiomers of R-Trans 
                                                 
90
 Yang et al., supra note 23, at 2. 
91
 See Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 15, 2009 
(S. Kor.) (stating that the pharmacological effects of anti-platelet aggregatory 
and anti-thrombotic and the effect of acute toxicity experiment “are explicitly 
stated in the detailed description of patent invention of this case.”). 
92
 Supreme Court [S. Ct.], 2008Hu3469 & 3476, Mar. 25, 2010 (S. Kor.); 
Supreme Court [S. Ct.], 2008Hu3520, Mar. 25, 2010 (S. Kor.); Supreme Court 
[S. Ct.], 2010Hu3424, Nov. 5, 2010 (S. Kor.). 
93
 Supreme Court [S. Ct.], 2008Hu3469 & 3476, Mar. 25, 2010 (S. Kor.) 
(concerning a dispute between Warner-Lambert Co. and Korean pharmaceutical 
companies as to an invalidation question); Supreme Court [S. Ct.], 2008Hu3520, 
Mar. 25, 2010 (S. Kor.) (concerning a dispute between Warner-Lambert Co. and 
KIPO as to a patentability question). 
94
 2008Hu3469 & 3476 and 2008Hu3520 are based on the same facts 
except that 2008Hu3469 & 3476 is an appeal against Korean pharmaceutical 
companies, and 2008Hu3520 is an appeal against KIPO. Supreme Court [S. Ct.], 
2008Hu3469 & 3476, Mar. 25, 2010 (S. Kor.); Supreme Court [S. Ct.], 
2008Hu3520, Mar. 25, 2010 (S. Kor.). 
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and S-Trans heptanoic acid were claimed as patentable.95 At the 
same time, the prior art disclosed the racemate of R-Trans and S-
Trans heptanoic acid.96 The Korean Supreme Court, citing Sanofi, 
held that enantiomers of those heptanoic acids are recognizable 
when the prior art discloses the racemate, and hence, the Korean 
Supreme Court denied the novelty of those claimed invention.97 
The Korean Supreme Court further clarified that the method of 
separating an enantiomer from its racemate is not relevant in 
examining novelty requirements.98 
B. Eli Lilly 
The most recent Korean Supreme Court case regarding 
selection invention is Eli Lilly from 2010.99   Though the issue 
before the Korean Supreme Court was not the patentability of an 
enantiomer invention, one must note that Eli Lilly is the first 
selection invention case in which the Korean Supreme Court did 
not invalidate the patent at issue.100 
V. WHY SO STRICT? 
As discussed previously, the Korean Supreme Court has been 
consistently hostile toward patentees, and such hostility peaked in 
                                                 
95
 Supreme Court [S. Ct.], 2008Hu3469 & 3476, Mar. 25, 2010 (S. Kor.); 
Supreme Court [S. Ct.], 2008Hu3520, Mar. 25, 2010 (S. Kor.). 
96
 Supreme Court [S. Ct.], 2008Hu3469 & 3476, Mar. 25, 2010 (S. Kor.); 
Supreme Court [S. Ct.], 2008Hu3520, Mar. 25, 2010 (S. Kor.). 
97
 Supreme Court [S. Ct.], 2008Hu3469 & 3476, Mar. 25, 2010 (S. Kor.). 
However, the Court does not specify the class to which the invention is 
recognizable. 
98
 See id. (stating that even if the lower court erred in finding that the prior 
art disclosed a method of separating an enantiomer from its racamate, such error 
had no impact on the decision, because disclosing such a method is not 
necessary in denying novelty of an invention at issue unless the subject matter of 
an invention is of the separating method). 
99
 Supreme Court [S. Ct.], 2010Hu3424, Nov. 5, 2010 (S. Kor). 
100
 See infra Part IV.C. 
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Sanofi as the Korean Supreme Court suggested strict patentability 
standards of selection invention. 101  This section provides legal 
analysis and persuasive policy justifications for such a strict 
standard. This section will further discuss the significance of Eli 
Lilly,102 which may be a signal for much changed attitude toward 
non-Korean pharmaceutical companies in the future. 
A. Legal Explanation 
The Sanofi holding is strict in that it greatly heightened both 
novelty and inventiveness standards.103 This section will discuss 
how such standards were legally heightened. 
1. Heightened Novelty Standard 
The Sanofi decision lacks a detailed inquiry, the presence of 
which may have resulted in a different outcome. Pursuant to 
Sanofi, structural similarity between a claimed composition and the 
prior art is grounds for a per se denial of the composition’s 
novelty.104 The most persuasive legal explanation for such per se 
analysis of novelty standards is a lack of the Korean Supreme 
Court’s judicial experience, which is especially true in the context 
of intellectual property law.105 Such lack of judicial experience is 
shown circumstantially from (1) the fact that the Korean Supreme 
Court has sometimes misapplied inventiveness criterions to 
novelty standards and (2) the Korean Supreme Court’s failure to 
                                                 
101
 See supra Part III.A. 
102
 Supreme Court [S. Ct.], 2010Hu3424, Nov. 5, 2010 (S. Kor.). 
103
 See generally Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 




 See Sang-Jo Jong, Contributory Patent Infringement in Korea, 2 WASH. 
U. J.L. & POL'Y 287, 287 (2000) (“Partly due to a lack of experience, courts have 
sometimes failed, in the course of interpreting provisions of the Patent Act, to 
balance the interests of the patentee and the interests of the general public.”). 
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distinguish scientific common knowledge and subject matter of an 
invention. 
i. Conceptual Misapplication 
One may easily find that the Korean Supreme Court 
conceptually misapplies inventiveness criterions to novelty 
standards. Such conceptual misapplication occurs when the Korean 
Supreme Court cites the perspective of a person having ordinary 
skill in the art in judging novelty. 106  Generally speaking, such 
conceptual misapplication heightened novelty standards by 
blurring the line between novelty and inventiveness. 107  The 
following discusses how the Korean Supreme Court conceptually 
misapplied inventiveness criterions in Sanofi. 
Article 29.1 of the Korean Patent Act defines novelty and 
Article 29.2 defines inventiveness.108 As is the case in the United 
States,109 only Article 29.2 discusses a “person having ordinary 
skill in the art” as a criterion for evaluating the inventiveness of an 
                                                 
106
 See Jung & Shin, supra note 84, at 390 (stating that citing the 
perspective of a person having ordinary skill in the art is a conceptual 
misapplication when judging the novelty standard). 
107
 See generally id. at 390. 
108
 See Erstling, supra note 9, at 451 (“The basis for the requirement of an 
‘inventive step’ is found in Article 29.2 of the Korean Patent Act, which 
provides that no patent for an invention may be granted if the invention could 
easily have been made before the filing of a patent application by a person with 
ordinary skill in the art to which the invention pertains.” (internal quotation 
marks omitted)); see also Teukheo beob [Patent Act], Act. No. 950, Dec. 31, 
1961, art. 29 (S. Kor.). 
109
 See 3 CARL R. MOY, MOY'S WALKER ON PATENTS § 9:1 (4th ed. 2013) 
(footnote omitted) (“[35 U.S.C. § 103(a)] states that an invention is not 
patentable if it would have been ‘obvious’ over the ‘prior art’ at the time the 
invention was made. Obviousness is to be judged from the objective perspective 
of ‘a person having ordinary skill in the art’ to which the invention pertains.”). 
22
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invention. 110  Therefore, using such a person’s perspective in 
judging the novelty of an invention itself is a conceptual 
misapplication of the law.111  
In Sanofi, the Korean Supreme Court committed this 
conceptual misapplication. As to Clopidogrel as the hydrochloride 
salt, Sanofi denied its novelty by reasoning that the presence of the 
invention is easily recognizable to a person having ordinary skill in 
the art from the prior art disclosing Clopidogrel and racemate as 
the hydrochloride salt.112 Regardless of whether the invention was 
recognizable to such a person, Sanofi uses the perspective of a 
person having ordinary skill in the art in denying novelty of the 
invention. 113  Erroneously, under the Korean Supreme Court’s 
reasoning, even though an invention at issue is not of the same 
invention disclosed in the prior art, the invention is anticipated for 
lack of novelty if the presence of the invention is recognizable to a 
person having ordinary skill in the art. 
a. Lack of Distinction between Scientific Common 
Knowledge and Subject Matter of an Invention 
In denying novelty of the invention, Sanofi cited the racemate 
patent disclosing PCR4099 and its enantiomers (Clopidogrel), 
which are the subject matter of the ’969 patent.114 Therefore, the 
Korean Supreme Court held that the subject matter of the racemate 
                                                 
110
 See Jung & Shin, supra note 84, at 391 (stating that while Korean Patent 
Act article 29.1 defines novelty and 29.2 defines inventiveness, the words “a 
person having ordinary skill in the art,” are only stated in 29.2). 
111
 See Jung & Shin, supra note 84, at 390 (stating that citing a perspective 
of a person having ordinary skill in the art is a conceptual misapplication in 
judging novelty standard). 
112
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patent was not only PCR 4099, but also Clopidogrel.115 However, 
the prior art neither stated that such enantiomers were substantially 
separated nor provided a clear motivation to indicate the 
enantiomers as its subject matter. 116  Regardless, the Korean 
Supreme Court held that prior art disclosed the Clopidogrel 
because it was scientifically common knowledge. Thus, Sanofi’s 
holding makes a prior art patent an anticipating reference even 
when the subject matter of the claimed invention has not been 
enabled by the prior art. 
Perceiving scientific common knowledge as the subject matter 
of an invention may be problematic. Though it is widely known 
that one of an enantiomer separated from its racemate may have 
greater pharmaceutical effect than that of its racemate, a lot of 
products are not available in the form of an enantiomer, since 
separating the enantiomer from its racemate is a very difficult 
process on which pharmaceutical companies usually spend 
considerable time and money.117 As such, the United States, along 
with Europe and Japan, have held that “knowledge that 
enantiomers may be separated is not anticipation of a specific 
enantiomer that has not been separated, identified, and 
characterized.”118 
                                                 
115
 Id. (“[E]ach enantiomer stated in the comparison invention No. 1 refers 
to dextro enantiomer and levo enantiomer and their mixture refers to racemate, 
so all of them, i.e., dextro enantiomer, levo enantiomer, and racemate, are the 
objects of invention of the comparison invention No. 1.”). 
116
 See Patent Court [Pat. Ct.], 2006Heo6303 & 8330, Jan. 18, 2008 (S. 
Kor.).  
117
 See Jung & Shin, supra note 84, at 392 (stating that the fact that Aventis 
invested a significant amount of money and time in developing a method of 
separating enantiomers from its racemate evidences that enantiomers are not 
easily separable from its racemate); see also Darrow, supra note 55, at 9 (“Due 
to the difficulty in separating the enantiomers from one another, many chiral 
drugs were initially sold in racemic form.”). 
118
 Sanofi-Synthelabo v. Apotex, Inc., 550 F.3d 1075, 1084 (Fed. Cir. 
2008). 
24
Cybaris®, Vol. 5, Iss. 2 [2014], Art. 4
http://open.mitchellhamline.edu/cybaris/vol5/iss2/4
[5:476 2014] CYBARIS®, AN INTELLECTUAL PROPERTY LAW REVIEW 500 
Despite the significant process of separating an enantiomer 
from its racemate, the Korean Supreme Court held in Sanofi that 
anticipating an enantiomer patent does not require disclosure of the 
process in the prior art.119 However, the patent was directed to the 
chemical structure itself, whereas if the patent had included a claim 
to the method of separation it may have been patentable. 
In conclusion, while other leading jurisdictions require further 
analysis on top of the mere presence of enantiomers,120 the Korean 
Supreme Court’s oversimplified holding in Sanofi substantially 
heightened the novelty standards by stating that scientific 
knowledge of the presence of an enantiomer in a racemate mixture 
anticipates a patent claiming an isolated enantiomer. 
2. Heightened Inventiveness Standard 
In examining whether the drug’s working effect is superior 
over the prior art, Sanofi further required that the working effect 
not be derived from routine experimentation, regardless of drug 
toxicity. 121  The possible legal explanation for a heightened 
inventiveness standard is relatively more obscure and complex 
than that of a novelty standard.  However, one may find a reason 
                                                 
119
 See Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 15, 2009 
(S. Kor.). Interestingly, the lower court held that mentioning the enantiomer 
itself is merely stating scientifically common knowledge unless the prior art 
discloses the separating method specifically. Accordingly, the lower court held 
that merely disclosing scientifically common knowledge itself does not deny 
novelty of the invention. See Patent Court [Pat. Ct.], 2006Heo6303 & 8330, Jan. 
18, 2008 (S. Kor.) (holding that disclosing enantiomers without (1) the method 
of separating those enantiomers from its racemate, (2) any experiment 
performing such separation, or (3) any motivation specifying enantiomers as 
subject matter is merely stating common scientific knowledge that racemate may 
exist in a form of one of enantiomer). 
120
 Sanofi-Synthelabo v. Apotex, Inc., 550 F.3d 1075, 1084 (Fed. Cir. 
2008). 
121
 Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 15, 2009 (S. 
Kor.). 
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for heightened inventiveness in unclear inventiveness criterions 
and misunderstanding of the nature of Article 29.2.  
i. Predictability 
Sanofi held that the working effect of the invention is obvious, 
and hence, inventiveness must be denied.122 Therefore, pursuant to 
Sanofi, superior working effect must not only be quantitatively 
superior, but also unpredictable. Sanofi seems to deal with the 
predictability very broadly. What the Korean Supreme Court found 
is not that an enantiomer drug always has a superior working effect 
over racemate drugs, but rather, that one of the enantiomer 
separated from the racemate may have superior working effect 
(superior enantiomer) over the other enantiomer (inferior 
enantiomer).123 Therefore, Sanofi concludes that it is obvious that 
an enantiomer drug consisting of superior enantiomers has, at least, 
a two-fold working effect over the racemate drug since superior 
enantiomers replace inferior enantiomers.124 
The predictability within the context of the Sanofi’s holding 
departs from one scientific possibility–that one enantiomer may be 
superior over the other, not that one enantiomer will likely be 
superior over the other. Therefore, Sanofi’s conception of the 
predictability is a very low threshold. 
ii. Toxicity 
In Sanofi, the Korean Supreme Court declined to consider 
toxicity of the enantiomer drugs as part of the predictability 
analysis.125 Rather, the Korean Supreme Court considered toxicity 
separated from a drug’s beneficial activity, and stated that the 






 Id.  
125
 See id. (holding that a drug’s toxicity will not be considered as a part of 
the inventiveness). 
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invention’s toxicity is only relevant in examining whether the 
invention can be used as medicinal product.126 
The Korean Supreme Court’s non-consideration of the toxicity 
for predictability heightened the inventiveness criteria as well. In 
Apotex,127 in which the United States Court of Appeals for the 
Federal Circuit dealt with same issue as was before the Korean 
Supreme Court in Sanofi, experts for both sides agreed that 
Clopidogrel’s degree and kind of stereoselectivity 128  was 
unpredictable since “activity and toxicity were more likely to be 
positively correlated, such that a reduction in toxicity would be 
expected also to reduce the beneficial activity.” 129  Therefore, 
consideration of toxicity as a part of predictability would have 
brought a different result regarding inventiveness. Still, in Sanofi, 
the Korean Supreme Court considered the drug’s beneficial 
activity only and asked whether such activity was predictable or 
not regardless the drug’s toxicity.130 
                                                 
126
 A drug is patentable under selection invention unless its toxicity exceeds 
the minimum threshold set by the court. See Patent Court [Pat. Ct.], 
2006Heo6303 & 8330, Jan. 18, 2008 (S. Kor.) (“[Toxicity] is just significant in 
examining whether it can be used as a medicinal product.”). 
127
 See Sanofi-Synthelabo v. Apotex, Inc., 550 F.3d 1075, 1078 (Fed. Cir. 
2008). 
128
 Id. at 1081 (Clopidogrel “provided all of the favorable antiplatelet 
activity but with no siginificant neurotoxicity, while the other enantiomer 
produced no antiplatelet activity but virtually all of the neurotoxicity.”). 
129
 See id. at 1087. 
130
 Therefore, Sanofi’s test may not treat the following inventions 
differently: one invention that is highly superior in beneficial activity with high 
toxicity, and the other invention that is highly superior in beneficial activity with 
almost no toxicity. Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 
15, 2009 (S. Kor.). 
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iii. Inventiveness Criterion 
The Sanofi decision does not specify a class of persons to 
whom such working effect may be obvious. 131  While one may 
infer from Article 29.2 that such a class may be persons having 
ordinary skill in the art, even assuming such is problematic since 
the Korean Supreme Court seems to misunderstand the nature of 
Article 29.2.132 
Inventiveness of selection invention derives from Article 29.2, 
which denies inventiveness when a person having ordinary skill in 
the art could easily have made the invention.133 Therefore, literal 
application of Article 29.2 to selection invention will not always 
deny inventiveness of an enantiomer patent by the prior art, which 
discloses the enantiomer’s racemate, since the fact that the 
enantiomer drug’s working effect is obvious or predictable does 
not necessarily indicate that the enantiomer drug could have been 
easily made.134 However, rather than asking whether the invention 
could have easily been made, the Korean Supreme Court asks 
whether the working effect is “obvious or well-known” to a person 
having ordinary skill in the art.135 
                                                 
131
 See generally id. 
132
 See Teukheo beob [Patent Act], Act. No. 950, Dec. 31, 1961, art. 29.2 
(S. Kor.) (“[A]n invention could easily have been made before the filing of a 
patent application by a person ordinarily skilled in the art to which the invention 
pertains, the patent for such an invention may not be granted.”). 
133
 See id. 
134
 It is general knowledge that one enantiomer may behave differently than 
another. See Darrow, supra note 55, at 8. However, such knowledge will not 
enable a person having ordinary skill in the art to practice an enantiomer drug 
since one must separate enantiomers first, and the separation is difficult process. 
Id. at 9. 
135
 Supreme Court [S. Ct.], 2008Hu736 & 743 (consol.), Oct. 15, 2009 (S. 
Kor.). 
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B. Protectionism? 
Though patentability of selection invention may be legally 
unreasonable, interestingly, such legally unreasonable standards 
serve the primary rationale of Korean Patent Act.136 This section 
provides possible explanation of the strict standard of selection 
invention in a term of policy justification by finding a causal 
connection between the strict standard and its impact on Korea’s 
pharmaceutical industry and its public. This section will first 
discuss the primary rationales of the Korean Patent Act, and then 
discuss how strict patentability standards of selection invention 
serve those rationales well. 
1. Rationales of the Korean Patent Act 
Narrowly, the rationale of the Korean Patent Act is to 
“contribute to the development of industry” by protecting and 
utilizing invention. 137  Broadly, the Korean Patent Act tries to 
further the public’s interest. 138  Therefore, the rationales of the 
Korean Patent Act are well-defined as dual in nature such that an 
invention that may undermine the industrial development or public 
interest is not patentable.139 Such dual nature of the Korean patent 
                                                 
136
 Teukheo beob [Patent Act], Act. No. 950, Dec. 31, 1961, art. 1 (S. Kor.) 
(stating in Article 1 that the “purpose of the [Korean Patent Act] is to encourage, 
protect and utilize inventions, thereby improving and developing technology, 
and to contribute to the development of industry.”). 
137
 See Erstling, supra note 9, at 448 (“[The Korean Patent Act] seeks both 
to protect and encourage inventions while at the same time promoting industrial 
development.”); see also Teukheo beob [Patent Act], Act. No. 950, Dec. 31, 
1961, art. 1 (S. Kor.). 
138
See Teukheo beob [Patent Act], Act. No. 950, Dec. 31, 1961, art. 32 (S. 
Kor.) (“An invention likely to contravene public order or morality or to injure 
public health may not be patented.”). 
139
 See KOREAN INTELL. PROP. OFFICE, A HISTORICAL ANALYSIS OF 
KOREAN PATENT ACT 3 (2007) (stating that an invention is not patentable if 
providing protection over the invention undermines industrial development or 
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system overrides an inventor’s patent rights so that giving 
incentives to patentees is deemed incidental in achieving the 
primary rationales.140 The fact that inventors’ rights are limited and 
open to governmental interference circumstantially supports this 
notion.141 
i. Impacts of the Korean Supreme Court’s Decision on 
Korean Pharmaceutical Industry 
The Korean Supreme Court’s consistent hostility toward 
patentees and applicants via strict novelty and inventiveness 
standards has several economic and social impacts, which perfectly 
serve the primary rationales of the Korean Patent Act.142 Those 
impacts include (1) to confer economic benefits and 
competitiveness to Korea’s domestic pharmaceutical industry via 
                                                                                                             
public interest as the Korean Patent Act intends to achieve both individual and 
public interest). 
140
 Article 1 does not mention rights of inventors. Rather, it mentions 
“protecting invention” through which, the Article 1 states, industrial 
development will be encouraged. See Teukheo beob [Patent Act], Act. No. 950, 
Dec. 31, 1961, art. 1 (S. Kor.). 
141
 Compared to that of the United States, an inventor’s rights under the 
Korean Patent Act are more limited and open to governmental interference. For 
instance, a patentee has an obligation to work the patented invention. See 
KOREAN INTELL. PROPERTY OFFICE, supra note 138, at 5 (stating that a 
patentee’s right over an invention may be interfered with if the patentee does not 
work or insufficiently works the invention pursuant to Korean Patent Act article 
107 or 116); see also Erstling, supra note 9, at 458 (discussion of the exceptions 
through which patentee’s exclusive right may be interfered and third party’s 
non-exclusive license to work a patented invention in a limited circumstances). 
Further, the fact that patent rights are freely assignable circumstantially supports 
the fact that inventors’ rights under Korean patent law are of less importance 
than that of the United States. See Erstling, supra note 9, at 453 (“Korea 
achieves an open marketplace under its patent law by providing that patents and 
their associated rights are freely assignable and otherwise transferable.”). 
142
 See infra Parts III.A, IV. 
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the preventing evergreening 143  strategy of non-Korean 
pharmaceutical industry, and (2) to lower drug prices so that the 
public may easily access the drug over which non-Korean 
pharmaceutical companies failed to gain or maintain patent rights. 
ii. Industrial Development 
Strict novelty and inventiveness standards of selection 
invention effectively prevent pharmaceutical companies’ 
evergreening strategies. This section explains why hostility toward 
evergreening strategies inevitably leads to substantial benefits to 
Korean pharmaceutical companies. Generally speaking, there 
exists a strong causal connection between the Korean Supreme 
Court’s hostility toward patentees and applicants and the Korean 
Patent Act’s primary rationale of industrial development. 
The idea that pharmaceutical products can be patentable is 
recent to the Korean Patent Act. Pharmaceutical products 
themselves were not patentable subject matter pursuant to Article 
32 until 1986, 144  primarily because the Korean pharmaceutical 
industry was not competitive enough to survive due to the leading 
pharmaceutical companies’ monopoly over the products.145 During 
the period when patent protection over pharmaceutical products 
                                                 
143
 See Janet Freilich, The Paradox of Legal Equivalents and Scientific 
Equivalence: Reconciling Patent Law's Doctrine of Equivalents with the FDA's 
Bioequivalence Requirement, 66 SMU L. REV. 59, 104-05 (2013) 
(“Evergreening . . . occurs when a pharmaceutical company that has lost both 
FDA exclusivity and patent protection on the active ingredient of its drug seeks 
to extend its monopoly by protecting the drug with a series of peripheral patents 
that allow for additional FDA exclusivity and further patent protection.”). 
144
 See Sang-Hyun Song & Seong-Ki Kim, The Impact of Multilateral 
Trade Negotiations on Intellectual Property Laws in Korea, 13 UCLA PAC. 
BASIN L.J. 118, 120 (1994). 
145
 Sang-Youn Hwang, A Prospect and Development Direction of Korean 
Pharmaceutical Industry, SHINYOUNG SECURITIES RESEARCH CENTER, 2000, at 
26. 
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was limited,146 Korean pharmaceutical companies learned how to 
manufacture finished drugs and active pharmaceutical ingredients 
(API),147 which became their major source of revenue.148 
Such protection over domestic pharmaceutical industries ended 
in 1986 due to bilateral trade negotiations.149 The United States 
asked Korea for stronger protection over pharmaceutical products, 
and Korea amended the Korean Patent Act to provide patent 
protection over chemical substances.150 Such protection was also 
conferred over pharmaceutical products per se.151 
Yet, one must note that the primary rationales of the Korean 
Patent Act were not the driving forces to such amendment. While 
the Korean Patent Act pursues industrial development and public 
interest, such an amendment was a result of recognizing a need for 
                                                 
146
 See Song & Kim, supra note 143, at 122 (“Since then the Patent Act has 
been revised several times, but protection for inventions of chemical substances 
per se was not allowed until 1987. Until then, only process patents were 
available for chemical inventions.”). 
147
 World Health Organization, Definition of Active Pharmaceutical 
Ingredient, at 3 (2011), available at http://www.who.int/medicines/areas/
quality_safety/quality_assurance/DefinitionAPI-QAS11-426Rev1-08082011.pdf 
(“Any substance or combination of substances used in a finished pharmaceutical 
product (FPP), intended to furnish pharmacological activity or to otherwise have 
direct effect in the diagnosis, cure, mitigation, treatment or prevention of 
disease, or to have direct effect in restoring, correcting or modifying 
physiological functions in human beings.”). 
148
 Hwang, supra note 144, at 26. 
149
 See KOREAN INTELL. PROPERTY OFFICE, supra note 138 at 206 (“As a 
result of bilateral agreement between Korea and United States, Korean Patent 
Act modified so that invention of pharmaceutical products, method of making 
the products, and pharmaceutical purpose become patentable.”). 
150
 See Song & Kim, supra note 144, at 121-22. 
151
 See id. at 122 (“As a result of the Korea-US trade negotiations in 1986, 
the Patent Act was amended to allow patent protection for chemical substances, 
pharmaceuticals, and agrochemicals. The patent term was also extended from 
twelve years to fifteen years. The amended Patent Act became effective July 1, 
1987.”). 
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foreign investment.152 Stated another way, Korea started providing 
patent protection over pharmaceuticals when Korean 
pharmaceutical companies were still not competitive against non-
Korean pharmaceutical companies. Because of this lack of 
competitiveness in the Korean pharmaceutical industry, the 
industry started investing in Research and Development on me-too 
drugs (also known as generic drugs),153 which have relatively low 
barriers to entry compared to other pharmaceuticals.154 
Therefore, the fact that selling generic drugs is a major source 
of profit for Korean pharmaceutical industries justifies the Korean 
Supreme Court’s willingness to donate inventions–once claimed to 
be selection inventions–to the public by invalidating or rejecting 
patentability of the invention, thereby leaving the invention 
available to all pharmaceutical companies. 
iii. Public Interest 
The Korean Supreme Court’s hostility toward patentees and 
applicants of selection inventions also confers some public interest 
by minimizing the social cost of patenting. The likelihood of 
invalidation or rejection of selection invention patents will 
encourage other pharmaceutical companies to manufacture generic 
                                                 
152
 See id. at 120 (“Realizing that foreigners will not invest in high-tech 
industries without adequate protection of their technologies, Korea reached a 
consensus on the positive role of intellectual property rights (“IPR”) in 
economic development.”). 
153
 Definition of Me-too drug, MEDICIENNET.COM (June 14, 2012), http://
www.medterms.com/script/main/art.asp?articlekey=33748 (defining me-too 
drug as “a drug that is structurally very similar to already known drugs, with 
only minor differences.”). 
154
 Hwang, supra note 144, at 26 (stating that Korean pharmaceutical 
companies in the 1980s used a strategy of developing generic drugs, which had a 
relatively low entry barrier, since Korean pharmaceutical companies had not had 
competitive development capacity of the products). 
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products of the rejected or invalidated invention.155 Such hostility 
toward monopoly will likely lower the drug price to which the 
invention pertains,156 and give the public alternative versions of the 
invention.157 This public interest will be served the most where 
pharmaceutical industry, like the Korean pharmaceutical industry, 
has “strong portfolio of generic products rather than expensive, 
branded drugs.”158 
iv. Turning Point? 
Out of the Korean Supreme Court cases involving selection 
invention, only one case, Eli Lilly, declined to invalidate a 
patent. 159  There, Hanmi Pharmaceutical Co., Ltd., a Korean 
company, brought a defensive action against Eli Lilly & Co., 
seeking to invalidate a patent. The patent at issue had more than 
one kind of quantitative and qualitative working effects. Therefore, 
the issue before the Korean Supreme Court was whether all of such 
working effects must be different than or superior to the prior art in 
order to possess inventiveness.160 In reversing and remanding the 
case to the Korean Intellectual Property Tribunal and Patent Court, 
the Korean Supreme Court declined to invalidate the patent by 
holding that inventiveness will be found even when only part of 
                                                 
155
 See Beom-Su Shin, Invalidation of Plavix Enabling Generic Products, 
DOCTOR’S NEWS (Jan. 18, 2008, 3:33 PM), http://www.doctorsnews.co.kr/news/
articleView.html?idxno=44797 (interviewing one of respondent of the Sanofi 
Patent, who stated that the company will continue produce generic products of 
Plavix). 
156
 See 1 CARL R. MOY, MOY'S WALKER ON PATENTS § 1:32 (4th ed. 2013). 
157
 See id. at § 1:33. 
158
 GBI Research, South Korea Pharmaceutical Market Outlook 2013, 
RESEARCH AND MARKETS (May 2013), http://www.researchandmarkets.com/
research/7d5t8r/south_korea. 
159
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those working effects are quantitatively different than or superior 
to that of the prior art.161 
It is significant that patentees of selection inventions at issues 
before the Korean Supreme Court had always been non-Korean 
pharmaceutical companies. The Korean Supreme Court, for the 
first time, declined to invalidate a non-Korean company’s patent of 
selection invention. Hence, one may argue that Eli Lilly is a 
turning point of the Korean Supreme Court’s trends that have 
unwaveringly favored its domestic pharmaceutical companies, and 
possibly signaling more favorable outcomes toward non-Korean 
pharmaceutical companies. The reasoning supporting this 
argument is two-fold. 
First, Eli Lilly lowered the selection invention’s patentability 
standard for the first time. Eli Lilly is not the first case dealing with 
an issue of multiple working effects. The Korean Supreme Court 
faced the same issue in 2001Hu2740 (Pfizer). However, the 
Korean Supreme Court’s holding in Pfizer was contrary to that in 
Eli Lilly.162 
In turn, The Korean Supreme Court had to overrule its holding 
in Pfizer. This is significant because Eli Lilly is the first case that 
actually lowered patentability standards, in favor of a patentee by 
overruling its prior decision.163 
Second, Eli Lilly seems to recognize this dispute as one 
between a foreign company and a domestic company, rather than 
one between a patentee and an alleged infringer. Such a view is 
                                                 
161
 See Id. 
162
 See Supreme Court [S. Ct.], 2001Hu2740, Apr. 25, 2003 (S. Kor.) 
(holding that all working effects of claimed selection invention must possess 
superior working effects over the prior art). 
163
 See Won-Joon Kim, The Inventive Step Decision when Partial 
Components of the Selection Invention have Noticeable Effects, 17 INFORMEDIA 
L. 1, 26 (2013). 
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implicitly indicated by the language of Eli Lilly. The Korean 
Supreme Court, when writing its opinions, always discloses the 
“main issues” by its own language. The Korean Supreme Court 
briefly gives readers an idea as to (1) the issues, (2) what will be 
discussed, and (3) a brief holding of the case. Generally speaking, 
the “main issues” section functions as a self-characterization of the 
opinion. 
Interestingly, Eli Lilly stated, in its “main issues,” that the 
opinion reversed the lower court’s holding, which denied 
inventiveness of patented selection invention, when the dispute 
was brought by a company against “foreign company.” 164 
Therefore, the language identifying a patentee as a “foreign 
company” may indicate that the Korean Supreme Court mitigated 
the selection invention’s patentability standard as a response to its 
hostile decisions toward foreign non-Korean pharmaceutical 
companies. The fact that identifying a patentee as a “foreign 
company,” limited to the cases regarding selection invention, has 
never been used before by the Korean Supreme Court further 
supports this position. 
VI. CONCLUSION 
Korean jurisdiction has been extremely strict against patentees 
of selection invention. Such hostility was especially true when an 
invention is either (1) structurally similar, or (2) only different in 
orientation to that of a prior art. Unless Sanofi is overturned, U.S. 
pharmaceutical companies will rarely succeed in seeking patent 
protection over those inventions and therefore, the evergreening 
strategy will likely fail as well. Though the Eli Lilly case favored a 
U.S. pharmaceutical company, in the future, one cannot rest easy 
by relying on only one case. More Korean Supreme Court 
decisions will help predicting future invalidation trends regarding 
the patentability of selection inventions. 
                                                 
164
 See 2 Supreme Court [S. Ct.], 2010Hu3424, Nov. 5, 2010 (S. Kor.). 
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